Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Lilly's solanezumab is in the same class as Pfizer and J&J's drug, but despite failing to hit its primary endpoints, the company has kept the development programme alive. Analysis of the data ...